Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

India’s Union Ministry of Health and Family Welfare has issued a notification ending the over-the-counter (OTC) sale of all syrups, including cough syrups.

Under the new rules, a doctor's prescription will now be required to purchase cough syrups across the country.

“Consequently, the sale and dispensing of cough syrups in smaller villages will now be required to take place only through duly licensed pharmacies in accordance with the provisions of the Drugs and Cosmetics Act, 1940 and the Rules framed thereunder,” the notification said.

Why Are the Rules Being Amended?

The amendment comes months after contaminated cough syrups were linked to the deaths of 22 children in Madhya Pradesh and Rajasthan, raising fresh concerns over the safety and regulation of commonly used liquid medicines.

Following the incident last year, health authorities in India had banned three cough syrups Coldrif, Respifresh TR and ReLife after traces of diethylene glycol (DEG) were detected in the products. The Coldrif contamination was linked to the deaths of 22 children in the country.

“The amendment has been undertaken to strengthen regulatory oversight of syrup formulations and to align the exemption framework with contemporary public health and safety requirements,” the notification said.

“The measure is expected to promote responsible distribution and sale of cough syrups while ensuring greater compliance with regulatory standards across the country,” it added.

Also read: Introducing Eggs Before Age One May Lower Allergy Risk by 17%, Says Study

Experts Welcome Move To Restrict Cough Syrup Sales

Dr Kuldeep Kumar Grover, Associate Director, Pulmonology and Critical Care, CK Birla Hospital, Gurugram called it a

"a good initiative to include all syrup varieties, cough syrups included, under prescription medicines".

Cough syrups have substances that might lead to drowsiness, addiction, or drug interaction in patients who do not seek medical advice before taking the medicines.

"It is important to note that a cough could be a symptom of other serious conditions like infections, asthma, and allergies. Prescription-based access encourages proper evaluation, accurate treatment, and safer medication use," Grover said.

Dr. (Prof.) Mohsin Wali, former Physician to the President of India, said cough syrups and similar formulations often contain suppressants such as codeine and dextromethorphan (DXM), along with other solvents.

Dr. Wali, Senior Consultant and Head of Preventive Cardiology at Pacific One Health, recalled previous incidents in which contaminated Indian-made cough syrups were linked to deaths in Gambia and other African countries.

"Industrial-grade solvents were detected in some of these products, leading to kidney failure, severe metabolic acidosis, and, in some cases, death," he said.

According to Dr. Wali, the new notification will help curb the overuse, misuse, and addictive use of cough syrups while improving patient safety.

What Did The Notification Say?

The Ministry notified an amendment to the Drugs Rules, 1945, through Gazette Notification G.S.R. 927(E) dated December 29, 2025, published in the Gazette of India Extraordinary, Part II, Section 3, Sub-section (i), dated December 30, 2025.

The amendment omits the word “Syrup” from Schedule K, Serial No. 13, Entry 7 under the heading “Class of Drugs.”

Schedule K of the Drugs Rules, 1945, provides exemptions from certain provisions of the Drugs and Cosmetics Act, 1940, and the rules framed under it for specified classes of drugs.

Before this amendment, Entry No. 13 of Schedule K permitted the sale of cough syrups in villages with a population of less than 1,000 without requiring compliance with certain retail sale licensing provisions.

With the omission of the word “Syrup” from the entry, this exemption will no longer apply to cough syrups.

Manufacturers, distributors, and retailers dealing with cough syrups have been advised to ensure strict compliance with the applicable licensing and regulatory requirements under the Drugs and Cosmetics Act, 1940, and the Drugs Rules, 1945.

Ban On Pediatric Cough Syrups

Last year, India formally prohibited the use of certain commonly available OTC cough and cold medicines in children below the age of four.

The policy move, notified through a gazette notification, banned a fixed-dose combination (FDC) of Chlorpheniramine Maleate and Phenylephrine Hydrochloride—two ingredients commonly found in pediatric cough syrups.

The decision followed growing global concerns over the safety of these medicines in very young children, with India joining several countries that have introduced stricter regulations.

Countries including the United States, Canada, and the United Kingdom had previously issued guidelines or warnings regarding the use of OTC cough and cold medicines in young children.

One month has passed since the Democratic Republic of the Congo (DRC) declared its 17th Ebola outbreak, and there is no sign of respite. Confirmed cases and deaths have surged to 808 and 192, respectively, according to the country's Health Ministry.

Uganda has confirmed 19 infections, while Congo's Ituri province, where the outbreak first emerged, accounts for more than 90% of cases in the country.

The outbreak was reported to the World Health Organization (WHO) and the outbreak was officially declared on May 15.

The cases continue to surge daily as health authorities and aid agencies grapple with inadequate testing, weak contact tracing, and community resistance.

However, experts warn the outbreak's true scale may be far greater than official data indicate, making it already the third-deadliest Ebola outbreak on record.

Ebola Epidemic Moving Upward

Also read: Ebola Survivors May Face COVID-Like Memory Loss and Brain Issues For Over 7 Years: NIH Study

According to Dieudonne Mwamba Kazadi, head of the DRC National Institute of Public Health (INSP), the Ebola epidemic was still moving upward in Bunia, the capital of Ituri province and the epicenter of the outbreak, Xinhua News Agency reported.

"We are still in the midst of the epidemic. I would say we are in the upward phase of the outbreak, the active phase," Kazadi said.

More confirmed cases are expected in the coming days, making it urgent to expand treatment capacity and establish new Ebola treatment centers in affected areas, he noted.

"The perspective is really to increase capacity and already have treatment centers positioned to receive the future suspected and confirmed cases that we will identify in the coming days and weeks," Kazadi said, stressing the need to "engaging communities further," he said.

True Scale of Outbreak Remains Unclear

Read More: Expert Explains Science Behind Ebola Patient Recoveries

Medical charity Medecins Sans Frontieres (MSF) said in a statement that the government's figures likely understate the true toll of the outbreak, echoing concerns raised by aid groups and some Congolese officials.

"No one knows the true scale or exactly where the disease is spreading in DRC," said Kate White, MSF's emergency medical coordinator.

"One month on, the Ebola disease outbreak is outpacing the response effort," White said.

She noted that most treatment centers in Ituri province are overwhelmed, with many patients arriving at a late stage of the disease.

"What we do know is that most treatment centers in Ituri province are overwhelmed; many of our patients arrive at a late stage of the disease, and the majority were never identified or monitored as contacts before seeking care," White said.

Testing and Contact Tracing Challenges

Testing remains "one of the most significant weaknesses in the response," according to the MSF statement.

WHO Director-General Tedros Adhanom Ghebreyesus said he was “really worried” about the outbreak after visiting the DRC, Stat News reported.

“When the community is not taking it as its priority, it’s very hard,’’ Tedros said. He said that in the North Kivu, South Kivu, and Ituri provinces where the outbreak is centered, Ebola is seen as a lesser evil compared with armed conflict, widespread hunger, and more common deadly diseases experienced daily.

Notably, many communities, particularly those affected by active armed conflict, still lack access to test kits. Treatment centers are also facing significant delays in receiving laboratory results, hampering efforts to quickly identify and isolate infections.

What Is Ebola?

Ebola is a highly lethal viral hemorrhagic fever first identified in 1976. Over the past five decades, it has caused over 30 outbreaks, primarily in Central and West Africa.

Symptoms include fever, headache, weakness, vomiting, diarrhea, muscle pain, sore throat, and unexplained bleeding. This eventually leads to severe complications like bleeding, organ failure, and death.

Aid groups warn that without stronger surveillance, faster testing, and improved contact tracing, the outbreak could continue to expand in the weeks ahead.

The United Kingdom is planning to create a new normal for children by banning social media for kids under 16. The services of social media, including Instagram and Snapchat, will not be available for adolescents in the island nation. The government there is planning to follow in the steps of Australia and block social media to ensure a safe and secure childhood.

To better protect children online and tackle growing digital risks, the government plans to introduce measures that go beyond a simple social media ban. Under the proposal, children under 16 would be blocked from accessing high-risk features such as livestreaming and communicating with strangers online. These world-leading restrictions would extend beyond social media platforms to cover a broader range of online services, including gaming websites, making the policy one of the most comprehensive child online safety measures introduced anywhere in the world.

Prime Minister Keir Starmer said, Parents want to keep their kids safe and happy, but the online world has made that harder than ever." He added, "I’ve heard firsthand from families crying out for change, and we will do right by them."

He also said that any country can ban social media for under-16s and put wider protections in place to give kids their childhood back.

Other Countries That Are Planning To Implement Social Media Ban

• Denmark: Plans to ban social media for children under 15, with limited parental exceptions for those aged 13–14.
• France: Approved a bill to ban social media for children under 15, pending final legislative approval.
• India: Karnataka has banned social media for children under 16. Other states like Andhra Pradesh, Goa, and Bihar are considering age restrictions.
• Italy: Children under 14 need parental consent to create social media accounts.
• Poland: Drafted legislation to ban social media for children under 15 and require age verification.
• Slovenia: Preparing a law that would prohibit social media access for children under 15.
• Spain: Plans to ban social media access for minors under 16 and require age verification.
• Sweden: A government commission has recommended a minimum social media age of 15.
• United States: Several states require parental consent for minors, while federal legislation seeks stronger protections for young users.
• European Union: Considering stricter child safety rules, including parental consent for under-16s and a ban for children under 13.

Which Countries Have Already Banned Or Imposed Curbs On Social Media Use By Children?

There are several nations that have already banned or implemented significant mechanisms to curb social media use by children. Australia, Malaysia, and Turkey have already passed laws to ban social media for children. On the other hand, China and Greece have made arrangements to curb the use of social media by children.